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Patients with reduced estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m2 have been excluded from 
randomized controlled trials of non–vitamin K antagonist oral 
anticoagulants for stroke prevention in atrial fibrillation (AF),1,2 
and the efficacy of warfarin specifically in patients with AF and 
reduced eGFR has never been established from randomized 
controlled trials. Furthermore, observational studies have led 
to doubts about the use of warfarin in this population.3,4
Only few observational studies have reported eGFR in 
AF cohorts, and these have generally focused on either the 
risk of stroke associated with reduced renal function without 
anticoagulation5 or the risk of bleeding associated with reduced 
renal function while on anticoagulation.3 Data on the risks asso-
ciated with mildly reduced renal function are sparse. We have 
previously studied the risk associated with coexisting chronic 
kidney disease and AF and the risks and benefits of anticoagula-
tion in these patients,6,7 but detailed levels of renal function based 
on creatinine measurements have not previously been available.
The aim of the current study was to examine the risk of stroke/
thromboembolism and major bleeding associated with reduced 
eGFR in a large Danish AF cohort and to evaluate the risk of 
stroke and bleeding associated with warfarin anticoagulation 
Background and Purpose—We sought to determine the risk of stroke/thromboembolism and bleeding associated with 
reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin 
treatment in specific estimated glomerular filtration rate (eGFR) groups.
Methods—We conducted a register-based cohort study and included patients discharged with nonvalvular  atrial fibrillation 
from 1997 to 2011 with available eGFR.
Results—A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated 
with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in 
all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97–1.56), 1.26 (95% CI, 1.14–1.40), 1.18 (95% CI, 
1.07–1.31), 1.11 (95% CI, 0.87–1.42), 2.01 (95% CI, 1.14–3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, 
and <15 mL/min per 1.73 m2, respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism 
in patients with eGFR ≥15 mL/min per 1.73 m2; hazard ratios 0.57 (95% CI, 0.43–0.76), 0.57 (95% CI, 0.51–0.64), 0.48 
(95% CI, 0.44–0.54), 0.60 (95% CI, 0.45–0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 
1.73 m2, respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with 
eGFR<15 mL/min per 1.73 m2; hazard ratio 1.18 (95% CI, 0.58–2.40).
Conclusions—In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. 
Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients 
with eGFR≥15 mL/min per 1.73 m2.   (Stroke. 2016;47:2707-2713. DOI: 10.1161/STROKEAHA.116.014422.)
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2708  Stroke  November 2016
according to the level of renal function categorized according to 
eGFR. We tested the hypotheses that the risk of stroke and bleed-
ing could be related to the level of renal function in patients with 
AF and that warfarin would be associated with higher risk of 
bleeding and lower risk of stroke independent of renal function.
Methods
Study Setting
In Denmark, every resident is provided with a unique and perma-
nent civil registration number that allows linkage of data from several 
nationwide registries on an individual level. In the Danish National 
Patient Registry, all patients discharged from a Danish hospital are 
coded according to the International Classification of Disease sys-
tem.8 All invasive therapeutic procedures are coded according to 
the Nordic Medical Statistics Committees Classification of Surgical 
Procedures. All prescriptions dispensed from Danish pharmacies 
are registered in the Danish Registry of Medicinal Product Statistics 
according to the Therapeutical Chemical system.9 The Danish Civil 
Registration System keeps information on vital status and cause of 
death for every citizen.10 The Danish Registry on Regular Dialysis 
and Transplantation holds complete and valid information on all 
Danish citizens treated with chronic renal replacement therapy.11
Study Population
We included all Danish residents discharged from a Danish hospital 
between 1997 and 2011 with a first-time primary diagnosis of AF or 
atrial flutter. Because information on medication relied on prescrip-
tion claims and pharmacotherapy could have been changed or inten-
sified in relation to index AF hospitalization, we began follow-up 7 
days after discharge. We excluded patients who experienced major 
bleeding, stroke/thromboembolism, or death within the 7-day period, 
patients >100 or <30 years, patients with valvular AF, patients who 
received dabigatran, and patients who received chronic renal replace-
ment therapy (hemodialysis, peritoneal dialysis, or kidney transplant). 
Patients were followed up until December 31, 2011, emigration, 
death, initiation of chronic renal replacement therapy, or event. All 
International Classification of Disease codes used to define the study 
population, comorbidities, and outcomes are shown in Table I in the 
online-only Data Supplement.
Estimating Renal Function
We identified all serum creatinine measurements available between 
1996 and 2011 from hospital laboratories in 3 different counties 
of Denmark. Serum creatinine measurements from the General 
Practitioner Laboratory of Copenhagen were also included. eGFR 
was calculated using the Chronic Kidney Disease Epidemiology 
Collaboration formulae.12 Baseline eGFR was estimated using the 
latest serum creatinine measurement up to 12 months before index 
AF hospitalization. For purposes of sensitivity, a mean eGFR was 
calculated for each patient based on all available serum creatinine 
measurements recorded within 12 months before index AF hospital-
ization. We categorized renal function as follows: eGFR ≥90, 60 to 
89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m2. Renal function 
was determined time dependently throughout follow-up, ie, patients 
could switch eGFR group according to latest eGFR every time a new 
serum creatinine measurement was made.
Pharmacotherapy and Comorbidities
Baseline pharmacotherapy was defined using redeemed prescriptions 
from 180 days before discharge to 7 days hereafter. Use of warfarin was 
estimated time dependently throughout follow-up, as previously done,7 
by dividing the number of redeemed tablets with an estimated daily dose. 
Comorbidities for our population were determined as done in previous 
studies.6,7
Study Outcomes
Outcomes under investigation were as follows: (1) death/hospitalization 
from stroke/thromboembolism and (2) death/hospitalization from major 
bleeding. Stroke/thromboembolism was defined using diagnosis codes 
for ischemic stroke, transient ischemic attack, or systemic thromboem-
bolism. Major bleeding was defined using diagnosis codes denoting 
severe gastrointestinal, intracranial, urinary tract, and airway bleeding.
Statistics
Incidence rates of stroke/thromboembolism and major bleeding 
according to renal function and warfarin treatment were estimated time 
dependently. The Aalen–Johansen method was used to determine the 
cumulative incidence of stroke/thromboembolism and major bleeding, 
accounting for competing risk of death. As sensitivity, this was also 
done using (1) only creatinine measurements from general practitioners 
Figure 1. Flowchart of the population selection. eGFR indicates estimated glomerular filtration rate.
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and (2) only creatinine tests from index AF hospitalization. The risk 
of stroke/thromboembolism and major bleeding associated with renal 
function for warfarin-anticoagulated and nonanticoagulated patients, 
respectively, was examined using time-dependent Cox proportional 
hazards models. Patients with eGFR≥90 mL/min per 1.73 m2 were used 
as reference. The risk of stroke/thromboembolism and major bleeding 
associated with warfarin treatment for patients with eGFR ≥90, 60 to 
89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m2 was examined 
using time-dependent Cox proportional hazards models. Patients who 
did not receive warfarin were used as reference. A 2-sided P<0.05 was 
considered statistically significant. All analyses were performed with 
SAS statistical software version 9.4 (SAS Institute Inc, Cary, NC) and 
R version 2.15.2 (R Development Core Team).
Ethics
Ethical approval is not required for retrospective registry-based studies 
in Denmark. The study was approved by the Danish Data Protection 
Agency (ref. no: 2007-58-0015/GEH-2014-012 I-Suite no: 02720).
Table 1. Characteristics at Baseline in Relation to Renal Status
 eGFR≥90 eGFR 60–89 eGFR 30–59 eGFR 15–30 eGFR<15
No. of patients 2522 7947 6163 624 93
Age, median (IQR), y 61 (52–69) 70 (62–78) 80 (73–85) 83 (77–88) 78 (69–87)
Last measurement
  eGFR, median (IQR) 100 (94–111) 73 (66 -81) 49 (42–55) 25.(21–28) 12 (9–14)
Measurements from the last year
  eGFR, median (IQR) 98 (91–109) 73 (66–80) 51 (43–57) 27 (23–31) 14 (12–18)
  No. of measurements, median (IQR) 2 (1–5) 3 (1–5) 3 (2–7) 7 (3–13) 11 (5–18)
Stroke comorbidity
  CHA
2
DS
2
-VASc, mean (SD) 1.53 (1.41) 2.44 (1.60) 3.59 (1.47) 4.32 (1.49) 3.81 (1.69)
  Heart failure 135 (5.4) 842 (10.6) 1380 (22.4) 266 (42.6) 35 (37.6)
  Hypertension 870 (34.5) 3518 (44.3) 3420 (55.5) 392 (62.8) 56 (60.2)
  Age ≥75 y 292 (11.6) 2892 (36.4) 4346 (70.5) 518 (83.0) 54 (58.1)
  Diabetes mellitus 226 (9.0) 593 (7.5) 571 (9.3) 106 (17.0) 20 (21.5)
  Previous stroke 199 (7.9) 829 (10.4) 967 (15.7) 132 (21.2) 19 (20.4)
  Vascular disease 250 (9.9) 1010 (12.7) 1258 (20.4) 208 (33.3) 30 (32.3)
  Age 65–74 y 661 (26.2) 2477 (31.2) 1340 (21.7) 83 (13.3) 26 (28.0)
  Women 738 (29.3) 3524 (44.3) 3545 (57.5) 339 (54.3) 41 (44.1)
Bleeding comorbidity
  HAS-BLED, mean (SD) 1.16 (1.05) 1.50 (0.97) 1.93 (0.86) 2.23 (0.89) 2.06 (0.91)
  Age >65 y 953 (37.8) 5369 (67.6) 5686 (92.3) 601 (96.3) 80 (86.0)
  Alcohol 215 (8.5) 280 (3.5) 128 (2.1) 14 (2.2) 5 (5.4)
  Liver disease 81 (3.2) 112 (1.4) 74 (1.2) 11 (1.8) <3
  Previous bleeding 159 (6.3) 429 (5.4) 477 (7.7) 81 (13.0) 15 (16.1)
  Hypertension 870 (34.5) 3518 (44.3) 3420 (55.5) 392 (62.8) 56 (60.2)
  Previous stroke 199 (7.9) 829 (10.4) 967 (15.7) 132 (21.2) 19 (20.4)
Medication at baseline
  Warfarin 818 (32.4) 3620 (45.6) 2730 (44.3) 219 (35.1) 20 (21.5)
  ADP receptor antagonist 61 (2.4) 230 (2.9) 207 (3.4) 26 (4.2) 6 (6.5)
  NSAID 500 (19.8) 1589 (20.0) 1317 (21.4) 176 (28.2) 17 (18.3)
  Aspirin 724 (28.7) 4916 (61.9) 3138 (50.9) 270 (43.3) 46 (49.5)
  β-blocker 1340 (53.1) 4547 (57.2) 3411 (55.3) 347 (55.6) 57 (61.3)
  Calcium channel blocker 545 (21.6) 2110 (26.6) 1891 (30.7) 205 (32.9) 33 (35.5)
  RASi 662 (26.2) 2659 (33.5) 2632 (42.7) 328 (52.6) 39 (41.9)
  Loop diuretics 379 (15.0) 2003 (25.2) 2837 (46.0) 480 (76.9) 69 (74.2)
CHA
2
DS
2
-VASc indicates congestive heart failure, hypertension, age 75 years (double weight), diabetes mellitus, stroke/thromboembolism (double weight), vascular 
disease, age 65–74, female sex; eGFR, estimated glomerular filtration rate (mL/min per 1.73 m2); HAS-BLED, hypertension, abnormal renal/liver function, previous 
stroke/thromboembolism, previous bleeding, labile international normalized ratio, elderly (age>75 years), alcohol abuse; IQR, interquartile range; NSAID, nonsteroidal 
anti-inflammatory drugs; and RASi, renin–angiotensin system inhibitors.
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Results
Characteristics of the Study Population
The selection of the study population is illustrated in Figure 1. 
We identified 101 752 patients with AF during the 15-year 
study period, and we excluded 6298 patients. Serum cre-
atinine was available at baseline in 17 349 of the remaining 
patients. Median age at baseline was 73 (interquartile range 
[IQR], 64–81) years, and 9162 (52.8%) were women. Table 1 
shows characteristics at baseline in relation to renal function.
Mean eGFR values calculated using all serum creatinine 
measurements from the last year before inclusion were com-
parable to the latest single eGFR measured before inclusion. 
Patients with eGFR 15 to 29 mL/min per 1.73 m2 were oldest 
and had the highest CHA2DS2-VASc (congestive heart failure, 
hypertension, age 75 years [double weight], diabetes mellitus, 
stroke/thromboembolism [double weight], vascular disease, 
age 65–74, female sex) and HAS-BLED scores (hypertension, 
abnormal renal/liver function, previous stroke/thromboembo-
lism, previous bleeding, labile international normalized ratio, 
elderly [age>75 years], alcohol abuse). Patients with eGFR 60 
to 89 mL/min per 1.73 m2 were most likely to receive warfarin 
treatment, and patients with eGFR <15 mL/min per 1.73 m2 
were least likely to receive warfarin treatment. Of the 2520 
patients in our study with CHA2DS2-VASc score 0 for men 
or 1 for women, 1541 (61.2%) had an eGFR <90 mL/min per 
1.73 m2 at baseline and 719 (28.5%) were in treatment with 
warfarin. Of the 93 patients with eGFR<15 mL/min per 1.73 
m2 at baseline, 17 (18.3%) initiated chronic renal replacement 
therapy during follow-up.
Follow-Up
Median follow-up was 4.0 (IQR, 1.4–7.8), 4.9 (IQR, 2.0–8.1), 
3.5 (IQR 1.3–6.7), 1.3 (IQR, 0.3–3.5), and 0.5 (IQR, 0.1–1.4) 
years in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, 
and <15 mL/min per 1.73 m2 at baseline, respectively.
Incidence of Stroke/Thromboembolism 
and Major Bleeding
Figure 2 shows 1-year cumulative incidence of stroke/ 
thromboembolism and major bleeding according to renal 
function determined at baseline. Lower eGFR was associated 
with greater cumulative incidence of both stroke/thromboem-
bolism and major bleeding.
Table 2 shows incidence rates of stroke/thromboembolism 
and major bleeding according to warfarin treatment and renal 
function. In patients with eGFR≥15 mL/min per 1.73 m2 rates 
of stroke/thromboembolism were lower among patients who 
received warfarin than among patients who did not receive 
warfarin, and rates of major bleeding were higher among 
patients who received warfarin than among patients who did 
not receive warfarin. Patients with eGFR<15 mL/min per 1.73 
m2 had comparable rates of stroke/thromboembolism on and 
off warfarin and higher rates of bleeding on warfarin than off 
warfarin.
Table 3 shows results from the multivariable adjusted Cox 
proportional hazard models on stroke/thromboembolism and 
major bleeding. A stepwise decrease in eGFR level was asso-
ciated with an incremental increase in risk of stroke/thrombo-
embolism and major bleeding when using eGFR≥90 mL/min 
per 1.73 m2 as a reference.
Figure 3 illustrates results from Cox proportional hazard 
models on stroke/thromboembolism and major bleeding 
associated with use of warfarin. In patients with eGFR≥15 
mL/min per 1.73 m2, warfarin was associated with lower risk 
of stroke. Warfarin was associated with higher bleeding risk 
across eGFR groups although insignificantly in patients with 
eGFR≥90 mL/min per 1.73 m2 (hazard ratio, 1.23; 95% con-
fidence interval, 0.97–1.56) and in patients with eGFR 15 to 
29 mL/min per 1.73 m2 (hazard ratio, 1.11; 95% confidence 
interval, 0.87–1.42). In patients with eGFR<15 mL/min per 
1.73 m2 not receiving dialysis, warfarin was not associated 
with lower risk of stroke (hazard ratio, 1.18; 95% confi-
dence interval, 0.58–1.40), but was associated with higher 
risk of bleeding (hazard ratio, 2.01; 95% confidence interval, 
1.14–3.54).
Figure 2. Cumulative incidence of stroke/thromboembolism and major bleeding according to eGFR. Renal function was determined with 
the last measurement available at baseline. The model is taking the risk of death from other causes (competing risks) into account. eGFR 
indicates estimated glomerular filtration rate.
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Sensitivity Analyses
Figures I and II in the online-only Data Supplement show cumu-
lative incidence of stroke/thromboembolism and major bleeding 
by renal function determined with serum creatinine measure-
ments obtained during index AF hospitalization. Figures III and 
IV in the online-only Data Supplement show cumulative inci-
dence of stroke/thromboembolism and major bleeding by renal 
function as determined by using only serum creatinine mea-
surements from general practitioners. In all analyses, Figures 
I through IV in the online-only Data Supplement, cumulative 
incidence of both stroke/thromboembolism and major bleeding 
were inversely correlated with eGFR. Figure V in the online-only 
Data Supplement shows median eGFR during the last 14 years 
before stroke/thromboembolism. For patients who experienced 
a stroke/thromboembolism, median eGFR decreased gradually 
during the study period, and our results were not driven by an 
immediate fall in eGFR before event.
Discussion
In this Danish cohort study including 17 349 AF patients with 
different levels of renal function, we found a stepwise higher 
risk of stroke/thromboembolism and major bleeding associated 
with decreasing levels of eGFR. Notably, the risk was higher 
in all patients with eGFR levels below 90 mL/min per 1.73 m2. 
Furthermore, warfarin treatment was associated with lower risk 
Table 2. Incidence Rates of Stroke/Thromboembolism and 
Major Bleeding per 100 Person-Years According to eGFR and 
Warfarin Treatment
Rates (95% CI; No. of Events)
Received Warfarin Did Not Receive Warfarin
15-y follow-up
  Stroke/thromboembolism
   eGFR≥90 1.54 (1.22–1.86; 88) 1.65 (1.43–1.86; 228)
   eGFR 60–89 1.73 (1.58–1.89; 455) 2.80 (2.64–2.96; 1120)
   eGFR 30–59 2.34 (2.13–2.55; 482) 5.30 (5.03–5.57; 1508)
   eGFR 15–29 4.36 (3.21–5.50; 56) 7.59 (6.51–8.67; 189)
   eGFR<15 14.47 (5.50–23.45; 10) 13.61 (8.17–19.06; 24)
  Major bleeding 
   eGFR≥90 2.55 (2.14–2.96; 149) 1.44 (1.24–1.64;198)
   eGFR 60–89 2.25 (2.07–2.43; 608) 1.74 (1.61–1.87; 700)
   eGFR 30–59 3.15 (2.91–3.39; 676) 2.96 (2.76–3.16; 862)
   eGFR 15–29 6.98 (5.53–8.43; 89) 6.40 (5.41–7.39; 161)
   eGFR<15 21.74 (11.09–32.40; 16) 12.70 (7.39–18.00; 22)
1-y follow-up
  Stroke/thromboembolism
   eGFR≥90 2.52 (1.55–3.48; 26) 2.71 (2.06–3.36; 67)
   eGFR 60–89 2.75 (2.25–3.25; 116) 4.09 (3.61–4.57; 279)
   eGFR 30–59 4.06 (3.34–4.79; 121) 8.54 (7.73–9.36; 423)
   eGFR 15–29 9.77 (5.38–14.16; 19) 13.57 (10.08–17.07; 58)
   eGFR<15 14.14 (0–33.74; 2) 14.51 (2.90–26.12; 6)
  Major bleeding 
   eGFR≥90 3.18 (2.09–4.26; 33) 1.94 (1.39–2.49; 48)
   eGFR 60–89 2.94 (2.43–3.46; 125) 2.88 (2.47–3.28; 196)
   eGFR 30–59 3.39 (2.73–4.05; 102) 4.30 (3.73–4.88; 215)
   eGFR 15–29 10.82 (6.19–15.44; 21) 8.98 (6.16–11.80; 39)
   eGFR<15 36.01 (4.45–67.57; 5) 25.51 (9.70–41.32; 10)
eGFR and warfarin treatment were estimated time dependently throughout 
follow-up. CI indicates confidence interval; and eGFR, estimated glomerular 
filtration rate (mL/min per 1.73 m2).
Table 3. Adjusted Hazard Ratio for Stroke/Thromboembolism 
and Major Bleeding According to eGFR and Warfarin Treatment
Hazard Ratio (95% Confidence Interval)
Received Warfarin Did Not Receive Warfarin 
15-y follow-up
  Stroke/thromboembolism*  
   eGFR≥90 1.00 (reference) 1.00 (reference)
   eGFR 60–89 1.90 (1.58–2.29) 1.23 (1.11 - 1.36)
   eGFR 30–59 1.86 (1.54–2.26) 1.50 (1.35 - 1.65)
   eGFR 15–29 3.21 (2.38–4.32) 1.94 (1.65–2.28)
   eGFR<15 11.55 (6.55–20.37) 4.11 (2.86–5.91)
  Major bleeding† 
   eGFR≥90 1.00 (reference) 1.00 (reference)
   eGFR 60–89 1.96 (1.67–2.31) 1.71 (1.35–2.16)
   eGFR 30–59 2.15 (1.82–2.54) 2.14 (1.69–2.72)
   eGFR 15–29 4.66 (3.65–5.94) 3.68 (2.54–5.34)
   eGFR<15 16.73 (10.79–25.96) 11.02 (6.04–20.10)
1-y follow-up
  Stroke/thromboembolism*  
   eGFR≥90 1.00 (reference) 1.00 (reference)
   eGFR 60–89 1.64 (1.22–2.22) 1.09 (0.91–1.30)
   eGFR 30–59 2.07 (1.51–2.83) 1.53 (1.29–1.80)
   eGFR 15–29 4.34 (2.62–7.20) 2.13 (1.60–2.83)
   eGFR<15 10.01 (3.15–31.82) 3.09 (1.52–6.26)
  Major bleeding† 
   eGFR≥90 1.00 (reference) 1.00 (reference)
   eGFR 60–89 1.87 (1.38–2.52) 1.26 (1.11–1.43)
   eGFR 30–59 1.77 (1.28–2.45) 1.48 (1.30–1.68)
   eGFR 15–29 4.54 (2.82–7.31) 3.11 (2.59–3.75)
   eGFR<15 30.60 (15.78–59.31) 8.79 (6.20–12.46)
eGFR indicates estimated glomerular filtration rate (mL/min per 1.73 m2).
*Model adjusted for congestive heart failure, hypertension, diabetes mellitus, 
previous stroke/thromboembolism, sex, age, vascular disease, and use of aspirin 
and ADP receptor antagonists. eGFR and warfarin treatment were estimated time 
dependently throughout follow-up.
†Model adjusted for hypertension, age, previous stroke, previous bleeding, 
liver disease, alcohol abuse, age, and use of aspirin and ADP receptor antagonists. 
eGFR and warfarin treatment were estimated time dependently throughout 
follow-up.
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of stroke in all patients with eGFR>15 mL/min per 1.73 m2, but 
not in patients with eGFR<15 mL/min per 1.73 m2. Warfarin 
was generally associated with higher risk of bleeding across all 
eGFR groups after adjustment for relevant risk factors.
Risk of Stroke and Bleeding Associated 
With Reduced eGFR
Kidney dysfunction is associated with an increase in inflam-
matory and procoagulant biomarkers, including C-reactive 
protein, fibrinogen, factor VII, and factor VIII13,14 and has been 
considered a marker of organ damage caused by hypertension 
or diabetes mellitus.2 Notably, kidney dysfunction as an inde-
pendent risk factor for stroke in AF has been garnering atten-
tion, and the addition of kidney dysfunction to various stroke 
risk stratification tools in AF has previously been studied.15,16 
On the contrary, kidney dysfunction is associated with hemo-
static dysfunction, including decreased levels of glycoprotein 
IIb and IIIa, decreased activity of von Willebrand Factor and 
altered arachidonic acid metabolism.17,18 Results from other 
cohorts have raised safety concerns on the use of warfarin in 
patients with severely reduced renal function.3 A recent cohort 
study by Jun et al3 reported gradually higher crude rates of 
bleeding associated with reduced renal function in patients 
with AF who received warfarin; however, after adjustment 
for relevant risk factors, this association was only significant 
among patients with eGFR<15 mL/min per 1.73 m2.
We found that all levels of eGFR<90 mL/min per 1.73 m2 
were associated with higher risk of stroke after adjustment 
for risk factors included in the CHA2DS2-VASc score. Of the 
2520 patients in our study with CHA2DS2-VASc score 0 for 
men or 1 for women, 1541 (61.15%) had an eGFR<90 mL/
min per 1.73 m2 at baseline and 719 (28.53%) were in treat-
ment with warfarin. Our study was not designed or powered to 
investigate the net clinical benefit of warfarin in these patients, 
but our results suggest that the CHA2DS2-VASc score would 
identify more patients with AF with increased risk of stroke if 
reduced renal function was included.
Risks and Benefits of Warfarin Treatment in 
Patients With Severely Reduced Renal Function
There are no published data from randomized trials of oral anti-
coagulation specifically in AF patients with eGFR<30 mL/min 
per 1.73 m2, and we are aware of only a single previous obser-
vational study with available creatinine measurements that has 
studied the safety and efficacy of warfarin in these patients.19 
Carrero et al19 found a lower risk of stroke/thromboembolism 
with warfarin in post–myocardial infarction AF patients with 
eGFR<15 mL/min per 1.73 m2. They also found lower bleeding 
rates on warfarin than on off warfarin, indicating possible selec-
tion bias, and the post–myocardial infarction nature of their 
study makes generalization to a broader AF population difficult. 
In the present study, warfarin treatment was associated with 
lower risk of stroke in all patients with eGFR>15 mL/min per 
1.73 m2, but not in patients with eGFR<15 mL/min per 1.73 m2.
We have previously found warfarin to be associated with 
lower risk of stroke, and all-cause mortality in patients with 
diagnosed non–end-stage chronic kidney disease and in 
patients on chronic renal replacement therapy. Creatinine mea-
surements have not previously been available for our cohort, 
but a previous sample of 110 diagnosed patients with non–
end-stage chronic kidney disease indicated that the majority of 
these patients (75.5%) had an eGFR>15 mL/min per 1.73 m2. 
Patients on chronic renal replacement therapy were excluded 
from the present study, and these patients were younger with 
less comorbidity than the patients with eGFR<15 mL/min per 
1.73 m2 analyzed in this study.
Clinical Implications
Our results highlight the importance of optimal renoprotective 
treatment to prevent stroke/thromboembolism and bleeding 
Figure 3. Adjusted hazard ratio (HR) for stroke/thromboembolism and major bleeding according to estimated glomerular filtration rate 
(eGFR) and warfarin treatment. The model with stroke/thromboembolism as outcome was adjusted for congestive heart failure, hyperten-
sion, diabetes mellitus, previous stroke/thromboembolism, sex, age, vascular disease, and use of aspirin and ADP receptor antagonists. 
Warfarin treatment and eGFR were estimated time dependently throughout follow-up. The model with major bleeding as outcome was 
adjusted for hypertension, age, previous stroke, previous bleeding, liver disease, alcohol abuse, age, and use of aspirin and ADP receptor 
antagonists. Warfarin treatment and eGFR were estimated time dependently throughout follow-up. CI indicates confidence interval.
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in patients with AF and mild to moderate reduced renal func-
tion. Our results also suggest that nondialysis AF patients with 
eGFR<15 mL/min per 1.73 m2 might not benefit from antico-
agulation therapy with warfarin. Because of their renal excre-
tion, non–vitamin K antagonist oral anticoagulants should not 
be used in patients with eGFR<15 mL/min per 1.73 m2 and 
our results suggest that physicians should not abstain from 
starting a non–vitamin K antagonist oral anticoagulants over 
warfarin in anticipation of a declining renal function; if the 
eGFR falls <15 mL/min per 1.73 m2, no anticoagulant should 
be used. At present, stroke prevention in this group of patients 
should focus on other factors than medical anticoagulation, ie, 
blood pressure control, smoking cessation, and a healthy diet. 
Future research should seek to develop new medical solutions 
for stroke prevention among patients with eGFR <15 mL/min 
per 1.73 m2.
Limitations
The study is limited by the observational design, and the small 
number of patients with eGFR<15 mL/min per 1.73 m2. We had 
no information on many clinical measures including interna-
tional normalized ratio, body mass index, smoking status, blood 
pressure, hemoglobin levels, blood lipid levels, and proteinuria, 
and residual confounding from these or other factors cannot be 
excluded. Creatinine measurements were only available from 3 
of 15 counties in Denmark. Thus, this reduced the number of 
patients available for inclusion. However, we had access to all 
serum creatinine measurements analyzed in the medical labora-
tories of these counties; hence, we have no reason to believe that 
this created substantial selection bias.
Conclusions
In a large Danish cohort of AF patients, risk of stroke/ 
thromboembolism and major bleeding were significantly associ-
ated with the level of renal function. Warfarin treatment was asso-
ciated with higher risk of bleeding in all eGFR groups and lower 
risk of stroke/thromboembolism in patients with eGFR >15 mL/
min per 1.73 m2.
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Supplemental Figure I. Cumulative Incidence of Stroke/thromboembolism according to Renal Function  
 
 
Caption: Cumulative Incidence of stroke/thromboembolism according to renal function. Renal function was determined 
at baseline. Only patients with creatinine measurements from index atrial fibrillation hospitalization were (n=10,486). 
The model is taking the risk of death from other causes (competing risks) into account.  
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Supplemental Figure II. Cumulative Incidence of Major bleeding according to Renal Function 
 
 
Caption: Cumulative Incidence of major bleeding according to renal function. Renal function was determined at 
baseline. Only patients with creatinine measurements from index atrial fibrillation hospitalization were included 
(n=10,486). The model is taking the risk of death from other causes (competing risks) into account.  
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Supplemental Figure III. Cumulative Incidence of Stroke/thromboembolism according to Renal Function 
 
 
Caption: Cumulative Incidence of stroke/thromboembolism according to renal function. Renal function was determined 
at baseline. Only patients with creatinine measurements from general practitioners (n=3,262) were included. The model 
is taking the risk of death from other causes (competing risks) into account.  
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Supplemental Figure IV. Cumulative Incidence of Major Bleeding according to Renal Function 
 
 
Caption: Cumulative Incidence of major bleeding according to renal function. Renal function was determined at 
baseline. Only patients with creatinine measurements from general practitioners (n=3,262) were included. The model is 
taking the risk of death from other causes (competing risks) into account.  
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Supplemental Figure V. Median eGFR before stroke 
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Supplemental Table 1. Diagnoses, surgical procedures, and pharmacotherapy used for defining the population, comorbidity, and outcomes 
 
Non-valvular atrial fibrillation  
Presence of ICD10:I48 
 ICD8: 4279 
Absence of:  
ICD8:39500, 39501, 39502, 39508, 39509, 39600, 3601, 39602, 39603, 39604, 39608, 
39609.  
 ICD10: Z952, Z954, I05, I06, I080A, I081A, I082A, I083A 
 NCSP: KFKD, KFKH, KFMD, KFMH, KFMA20, KFMA32A, KFGE, KFJF 
 
Comorbidity 
Diabetes Mellitus Defined from treatment Treatment: Glucose-lowering medication 
Heart Failure Defined from diagnosis and treatment ICD8: 425, 4270-4271 
  ICD10: I110, I42, I50, J819. 
  Treatment: Loop-diuretics.  
Hypertension Defined from combined treatment with at  Treamtent: Renin-angiotensin system inhibitors, calcium channel  
 least two classes of antihypertensive drugs.  blockers, vasodilators, non-loop-diuretics, adrenergic α-antagonists.  
 This definition has a specificity of 94.7 % and  
 a positive predictive value of 80.0%  
Previous   
stroke/thromboembolism Defined from diagnosis ICD8: 433-438, 444 
  ICD10: G458-459, I63-I64, I74  
Vascular disease Defined from diagnosis ICD8: 410, 440 
  ICD10: I21-I22, I700, I702-I709 
Alcohol Abuse Defined from diagnosis and reported ICD8: 291, 303, N979-N980 
 adverse alcohol consumption during  ICD10: E244, E52, F1, G312, G621, G721, I426, K292, K70, K860, L278A, 
 hospitalization O354, T51, Z714, Z721.  
Drug consumption Defined from treatment with non-steroidal Treatment: NSAID's.  
 anti-inflammatory drugs.   
8 
 
Liver Disease Defined from diagnosis ICD8: 070, 155, 571-573. 
  ICD10: B15-B19, C22, D684C, I982B, K70-K77, DQ618A, Z944.  
Previous Bleeding Defined from diagnosis ICD8:  430-431, N852-N853 
  ICD10: I60-I62, I690-I692, J942, K250, K254, K260, K264, K270, K280,  
  K920-K922, N02, R04, R31, S064-S066. 
 
Outcomes 
Stroke/thromboembolism Death from or diagnosis of peripheral arterial  ICD10: G458-G459, I63-I64, I74.  
 embolism, stroke, and transient ischemic attack  
Major Bleeding Death from or diagnosis of gastrointestinal,  ICD10: I60-I62, I690-I692, J942, K250, K254, K260, K264, K270, K280,  
 intracranial, urinary tract or airway bleeding K920-K922, N02, R04, R31, S064-S066.  
 
ICD8: 8th revision of the International Classification of Diseases system 
ICD10: 10th revision of the International Classification of Diseases system 
NCSP: The Nordic Medical Statistics Committees Classification of Surgical Procedures 
 
 
 
